Bladder transitional cell carcinoma
Not recruitingStudy of erdafitinib versus chemotherapy (gemcitabine or mitomycin) for patients with high-risk non-muscle-invasive bladder cancer with FGFR mutations who failed BCG therapy
Study of erdafitinib versus chemotherapy (gemcitabine or mitomycin) for patients with high-risk non-muscle-invasive bladder cancer with FGFR mutations who failed BCG therapy
- Disease:Bladder transitional cell carcinoma
- Substances:ErdafitinibGemcitabine+1
Germany- Participants:18–64 years · 65+ years
- Substances:Erdafitinib
